About: Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS‐CoV‐2

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS‐CoV‐2 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS‐CoV‐2
Creator	Budev, Marie Asadi, Tannaz Calabrese, Casandra Canosa, Francisco Correspondence, Jose Gastman, Brian Koval, Christine Kv, Narayanan Menon, Morillas, Morillas, Jose Poggio, Emilio Rajendram, Prabalini Srinivas, Pavithra
Source	Medline; PMC
abstract	There is emerging data depicting the clinical presentation of COVID‐19 in solid organ transplant recipients but negligible data‐driven guidance on clinical management. A biphasic course has been described in some infected with SARS‐CoV‐2, beginning with a flu‐like illness followed by an intense inflammatory response characterized by elevated c‐reactive protein (CRP), interleukin 6 (IL‐6), and acute respiratory distress syndrome (ARDS) associated with high mortality. The exuberant and possibly dysregulated immune response has prompted interest in therapeutic agents that target the cytokines involved, particularly IL‐6. Tocilizumab is an IL‐6 receptor antagonist with a record of use for a variety of rheumatologic conditions and cytokine release syndrome due to CAR T‐cell therapy but experience in solid organ and composite tissue transplant recipients (SOT/CTTRs) with SARS‐CoV‐2‐related ARDS has not been previously reported in detail. We present the clinical course of five SOT/CTTRs with SARS‐CoV‐2‐related ARDS that received tocilizumab with favorable short‐term outcomes in four. Responses were characterized by reductions in CRP, discontinuation of vasopressors, improved oxygenation and respiratory mechanics, and variable duration of ventilator support. Four bacterial infections occurred within two weeks of tocilizumab administration. We discuss safety concerns and the need for randomized comparative trials to delineate tocilizumab’s clinical utility in this population.
has issue date	2020-05-31(xsd:dateTime)
bibo:doi	10.1111/ajt.16080
bibo:pmid	32476261
has license	no-cc
sha1sum (hex)	9b5e9dd21ddd37656dc1b99a97cf06c8bd72274d
schema:url	https://doi.org/10.1111/ajt.16080
resource representing a document's title	Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS‐CoV‐2
has PubMed Central identifier	PMC7300992
has PubMed identifier	32476261
schema:publication	Am J Transplant
resource representing a document's body	covid:9b5e9dd21ddd37656dc1b99a97cf06c8bd72274d#body_text
is schema:about of	named entity 'TOCILIZUMAB' named entity 'CRP' named entity 'long term care' named entity 'case series' named entity 'immune response' named entity 'cyclosporine' named entity 'creatinine' named entity 'signs of infection' named entity 'inflammation' named entity 'PEEP' named entity 'SpO2' named entity 'acute renal failure' named entity 'hepatitis' named entity 'lung' named entity 'hemodialysis' named entity 'tocilizumab' named entity 'emergency department' named entity 'empiric' named entity 'immune suppression' named entity 'atrial fibrillation with rapid ventricular response' named entity 'hypotension' named entity 'bacterial infection' named entity 'SOB' named entity 'multidrug-resistant' named entity 'turn-around time' named entity 'aspirate' named entity 'graft surgery' named entity 'CRP' named entity 'azathioprine' named entity 'COVID' named entity 'fever' named entity 'blood sample' named entity 'CXR' named entity 'lung' named entity 'ARDS' named entity 'ceftriaxone' named entity 'Empiric' named entity 'tocilizumab' named entity 'RSV' named entity 'ICU' named entity 'ALC' named entity 'immune response' named entity 'SARS-CoV-2' named entity 'tocilizumab' named entity 'organ' named entity 'case series' named entity 'CRP' named entity 'COVID-19' named entity 'respiratory distress' named entity 'azithromycin' named entity 'tocilizumab' named entity 'colistin' named entity 'influenza' named entity 'CRP' named entity 'lung' named entity 'C-reactive protein' named entity 'IL-6' named entity 'ALC' named entity 'diabetes mellitus' named entity 'mmol/L' named entity 'SpO2' named entity 'ferritin' named entity 'tocilizumab' named entity 'kidney transplantation' named entity 'lopinavir/ritonavir' named entity 'vasopressors' named entity 'American Journal of Transplantation' named entity 'mechanical ventilation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software